EA201692050A1 - Лечение неалкогольной жировой болезни печени и неалкогольного стеатогепатита - Google Patents

Лечение неалкогольной жировой болезни печени и неалкогольного стеатогепатита

Info

Publication number
EA201692050A1
EA201692050A1 EA201692050A EA201692050A EA201692050A1 EA 201692050 A1 EA201692050 A1 EA 201692050A1 EA 201692050 A EA201692050 A EA 201692050A EA 201692050 A EA201692050 A EA 201692050A EA 201692050 A1 EA201692050 A1 EA 201692050A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
steatogepatitis
fatial
alcoholic
liver
Prior art date
Application number
EA201692050A
Other languages
English (en)
Other versions
EA036704B1 (ru
Inventor
Брайан РОБЕРТС
Сюэянь Ванг
Юнь-Цзюн Чой
Дэвид Карпф
Роберт Мартин
Чарльз А. Макуэртер
Original Assignee
Саймабэй Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692050(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Саймабэй Терапьютикс, Инк. filed Critical Саймабэй Терапьютикс, Инк.
Publication of EA201692050A1 publication Critical patent/EA201692050A1/ru
Publication of EA036704B1 publication Critical patent/EA036704B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Лечение НАЖБП или НАСГ с помощью терапии МВХ 8025 или солью МВХ 8025.
EA201692050A 2014-04-11 2015-04-10 Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита EA036704B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11
PCT/US2015/025416 WO2015157697A1 (en) 2014-04-11 2015-04-10 Treatment of nafld and nash

Publications (2)

Publication Number Publication Date
EA201692050A1 true EA201692050A1 (ru) 2017-01-30
EA036704B1 EA036704B1 (ru) 2020-12-10

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692050A EA036704B1 (ru) 2014-04-11 2015-04-10 Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита

Country Status (26)

Country Link
US (7) US9381181B2 (ru)
EP (1) EP3129018B1 (ru)
JP (1) JP6865038B2 (ru)
KR (1) KR102374499B1 (ru)
CN (1) CN106163508A (ru)
AU (1) AU2015243239B2 (ru)
BR (1) BR112016023269A8 (ru)
CA (1) CA2944139C (ru)
CL (1) CL2016002517A1 (ru)
CY (1) CY1122602T1 (ru)
DK (1) DK3129018T3 (ru)
EA (1) EA036704B1 (ru)
ES (1) ES2764467T3 (ru)
HR (1) HRP20192299T1 (ru)
IL (1) IL248193B (ru)
LT (1) LT3129018T (ru)
MX (1) MX369921B (ru)
NZ (1) NZ724740A (ru)
PH (1) PH12016501978A1 (ru)
PL (1) PL3129018T3 (ru)
PT (1) PT3129018T (ru)
RS (1) RS59637B1 (ru)
SG (1) SG11201608077PA (ru)
SI (1) SI3129018T1 (ru)
UA (1) UA121208C2 (ru)
WO (1) WO2015157697A1 (ru)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
ES2712052T3 (es) * 2008-10-17 2019-05-09 Cymabay Therapeutics Inc Métodos para reducir partículas de LDL pequeñas y densas
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
BRPI1011876B1 (pt) 2009-04-29 2020-03-31 Amarin Pharma, Inc. Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular
DK2443246T3 (en) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ie Ltd COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDES WITHOUT INCREASING LDL-C LEVELS IN AN INDIVIDUAL WITH CURRENT STATE THERAPY
RU2012116079A (ru) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
EP4342546A3 (en) 2012-06-29 2024-05-22 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
BR112016020260A8 (pt) 2014-03-20 2021-06-29 Cymabay Therapeutics Inc uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
DK3129018T3 (da) 2014-04-11 2020-01-20 Cymabay Therapeutics Inc Behandling af NAFLD og NASH
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
CA2980296A1 (en) * 2015-03-26 2016-09-29 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives
CN115025079A (zh) 2015-04-28 2022-09-09 普罗诺瓦生物医药挪威公司 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en) * 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
CN117229994A (zh) * 2016-11-04 2023-12-15 儿童医院医学中心 肝类器官疾病模型以及其制备和使用方法
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
SG10202105768WA (en) 2016-12-05 2021-06-29 Childrens Hospital Med Ct Colonic organoids and methods of making and using same
WO2018204775A1 (en) 2017-05-05 2018-11-08 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2019053582A1 (en) 2017-09-13 2019-03-21 Novartis Ag COMBINATIONS HAVING FXR AGONISTS
CN111511372A (zh) * 2017-10-27 2020-08-07 株式会社三养社 预防或减轻非酒精性脂肪肝疾病的组合物
WO2019111048A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US20200155487A1 (en) * 2018-11-16 2020-05-21 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
AU2019378845A1 (en) * 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
AU2021273487A1 (en) * 2020-05-13 2023-01-05 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
WO2022238450A1 (en) * 2021-05-11 2022-11-17 Genfit Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
WO1996027606A1 (en) 1995-03-06 1996-09-12 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
BR9707529A (pt) 1996-02-14 2000-01-04 Isis Pharmaceuticals Inc Oligunucleotìdeo especificamente hibridizável com dna ou rna.
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
SI1667964T1 (sl) 2003-09-19 2009-12-31 Janssen Pharmaceutica Nv 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi
AU2005221656B2 (en) 2004-03-05 2011-06-23 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
ES2712052T3 (es) 2008-10-17 2019-05-09 Cymabay Therapeutics Inc Métodos para reducir partículas de LDL pequeñas y densas
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2015077154A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
BR112016020260A8 (pt) 2014-03-20 2021-06-29 Cymabay Therapeutics Inc uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
DK3129018T3 (da) 2014-04-11 2020-01-20 Cymabay Therapeutics Inc Behandling af NAFLD og NASH
BR112016028918A2 (pt) 2014-06-26 2017-08-22 Cymabay Therapeutics Inc tratamento de hipertrigliceridemia grave

Also Published As

Publication number Publication date
AU2015243239A1 (en) 2016-10-20
CA2944139A1 (en) 2015-10-15
EP3129018B1 (en) 2019-10-23
PT3129018T (pt) 2020-01-15
AU2015243239B2 (en) 2019-11-14
UA121208C2 (uk) 2020-04-27
CY1122602T1 (el) 2021-03-12
US11179359B2 (en) 2021-11-23
US20190142776A1 (en) 2019-05-16
WO2015157697A1 (en) 2015-10-15
US10722483B2 (en) 2020-07-28
US20180008566A1 (en) 2018-01-11
JP2017513836A (ja) 2017-06-01
NZ724740A (en) 2019-11-29
US10342770B2 (en) 2019-07-09
SG11201608077PA (en) 2016-10-28
BR112016023269A8 (pt) 2021-06-29
US9616039B2 (en) 2017-04-11
US20210038546A1 (en) 2021-02-11
PL3129018T3 (pl) 2020-05-18
CA2944139C (en) 2020-11-03
EP3129018A1 (en) 2017-02-15
US20180228752A1 (en) 2018-08-16
MX2016013375A (es) 2017-02-15
LT3129018T (lt) 2020-01-10
JP6865038B2 (ja) 2021-04-28
US20160324812A1 (en) 2016-11-10
CN106163508A (zh) 2016-11-23
KR102374499B1 (ko) 2022-03-14
EA036704B1 (ru) 2020-12-10
BR112016023269A2 (pt) 2017-08-15
US20200009092A1 (en) 2020-01-09
SI3129018T1 (sl) 2020-02-28
US20150290154A1 (en) 2015-10-15
KR20160136451A (ko) 2016-11-29
HRP20192299T1 (hr) 2020-03-06
IL248193B (en) 2019-03-31
MX369921B (es) 2019-11-26
RS59637B1 (sr) 2020-01-31
US9381181B2 (en) 2016-07-05
US9962346B2 (en) 2018-05-08
CL2016002517A1 (es) 2017-05-05
ES2764467T3 (es) 2020-06-03
US10188620B2 (en) 2019-01-29
PH12016501978A1 (en) 2016-12-19
DK3129018T3 (da) 2020-01-20

Similar Documents

Publication Publication Date Title
EA201692050A1 (ru) Лечение неалкогольной жировой болезни печени и неалкогольного стеатогепатита
EA201790737A1 (ru) Комбинированная терапия
EA201790413A1 (ru) Антитела против tigit
EA201790913A1 (ru) Лечение заболеваний, связанных с активацией звездчатых клеток печени, с применением видов терапии, снижающих уровень аммиака
EA201792562A1 (ru) Глюкагон и коагонисты гпп-1
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CL2017000806A1 (es) Compuestos anti-tnf
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
PH12018501443A1 (en) Methods of administering hepcidin
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201891299A1 (ru) Терапевтические антитела к cd9
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
PH12016501838A1 (en) Compounds and their methods of use
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
PH12019501358A1 (en) Methods of administering hepcidin
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
EA201790537A1 (ru) Дипептидилкетоамидные соединения и их применение для лечения и/или предотвращения накопления жира